Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients.
10.1007/s11684-018-0616-1
- Author:
Yang ZHANG
1
;
Fang WANG
1
;
Xue CHEN
1
;
Wenjing LIU
1
;
Jiancheng FANG
1
;
Mingyu WANG
1
;
Wen TENG
1
;
Panxiang CAO
1
;
Hongxing LIU
2
Author Information
1. Pathology & Laboratory Medicine Division, Hebei Yanda Lu Daopei Hospital, Lang fang, 065201, China.
2. Pathology & Laboratory Medicine Division, Hebei Yanda Lu Daopei Hospital, Lang fang, 065201, China. lhongxing@outlook.com.
- Publication Type:Journal Article
- Keywords:
acute;
gene;
leukemia;
mutation;
myeloid
- MeSH:
Adolescent;
Adult;
Aged;
CCAAT-Enhancer-Binding Proteins;
genetics;
Child;
Child, Preschool;
China;
DNA Mutational Analysis;
Female;
GTP Phosphohydrolases;
genetics;
Gene Expression Profiling;
Gene Frequency;
Genetic Predisposition to Disease;
Humans;
Kaplan-Meier Estimate;
Leukemia, Myeloid, Acute;
genetics;
Male;
Membrane Proteins;
genetics;
Middle Aged;
Mutation;
Nuclear Proteins;
genetics;
Phenotype;
Retrospective Studies;
Young Adult;
fms-Like Tyrosine Kinase 3;
genetics
- From:
Frontiers of Medicine
2019;13(2):229-237
- CountryChina
- Language:English
-
Abstract:
This retrospective analysis aimed to investigate the mutation profile of 16 common mutated genes in de novo acute myeloid leukemia (AML) patients. A total of 259 patients who were diagnosed of de novo AML were enrolled in this study. Mutation profiling of 16 candidate genes were performed in bone marrow samples by using Sanger sequencing.We identified at least 1 mutation in 199 of the 259 samples (76.8%), and 2 or more mutations in 31.7% of samples. FLT3-ITD was the most common mutated gene (16.2%, 42/259), followed by CEBPA (15.1%, 39/259), NRAS (14.7%, 38/259), and NPM1 (13.5%, 35/259). Concurrence was observed in 97.1% of the NPM1 mutated cases and in 29.6% of the double mutated CEBPA cases. Distinct patterns of co-occurrence were observed for different hotspot mutations within the IDH2 gene: R140 mutations were associated with NPM1 and/or FLT3-ITD mutations, whereas R172 mutations co-occurred with DNMT3A mutations only. Concurrence was also observed in 86.6% of epigenetic regulation genes, most of which co-occurred with NPM1 mutations. The results showed certain rules in the mutation profiling and concurrence of AML patients, which was related to the function classification of genes. Defining the mutation spectrum and mutation pattern of AML will contribute to the comprehensive assessment of patients and identification of new therapeutic targets.
